GYRE THERAPEUTICS, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $116.6M | $105.8M | $113.5M | $102.3M | $7.3M |
| Gross profit | — | $101.9M | $108.8M | $97.5M | — |
| Operating income | $11.5M | $16.2M | -$67.2M | $9.2M | -$87.9M |
| Operating expenses | $105.1M | $89.6M | $176.0M | $88.3M | $95.2M |
| Cost of revenue | $5.4M | $3.9M | $4.6M | $4.8M | — |
| Cash from operations | $1.0M | -$3.6M | $25.9M | $10.7M | -$83.8M |
| Capital expenditure | $1.2M | $2.3M | $8.5M | $5.0M | $839,000 |
| Free cash flow | -$180,000 | -$6.0M | $17.4M | $5.7M | -$84.6M |
| Impairments | $0 | $0 | $0 | $0 | — |
| Total assets | $166.1M | $125.4M | $116.5M | $84.8M | $55.7M |
| Total liabilities | $23.9M | $27.0M | $38.1M | $12.5M | $14.6M |
Shares outstanding 97.0M · Free float 10.3%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.